DE69633186D1 - Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren - Google Patents

Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren

Info

Publication number
DE69633186D1
DE69633186D1 DE69633186T DE69633186T DE69633186D1 DE 69633186 D1 DE69633186 D1 DE 69633186D1 DE 69633186 T DE69633186 T DE 69633186T DE 69633186 T DE69633186 T DE 69633186T DE 69633186 D1 DE69633186 D1 DE 69633186D1
Authority
DE
Germany
Prior art keywords
rac
protein kinase
interact
screening
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633186T
Other languages
English (en)
Other versions
DE69633186T2 (de
Inventor
Arthur Hemmings
Philip Cohen
Dario Alessi
Darren Cross
Mirjana Andjelkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523379.7A external-priority patent/GB9523379D0/en
Priority claimed from GBGB9525704.4A external-priority patent/GB9525704D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69633186D1 publication Critical patent/DE69633186D1/de
Application granted granted Critical
Publication of DE69633186T2 publication Critical patent/DE69633186T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69633186T 1995-11-16 1996-11-05 Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren Expired - Lifetime DE69633186T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9523379 1995-11-16
GBGB9523379.7A GB9523379D0 (en) 1995-11-16 1995-11-16 Compound and method
GBGB9525704.4A GB9525704D0 (en) 1995-12-15 1995-12-15 Ligand and screening method
GB9525704 1995-12-15
PCT/EP1996/004810 WO1997018303A1 (en) 1995-11-16 1996-11-05 Rac-proteine kinase as therapeutic agent or in diagnostics

Publications (2)

Publication Number Publication Date
DE69633186D1 true DE69633186D1 (de) 2004-09-23
DE69633186T2 DE69633186T2 (de) 2005-08-18

Family

ID=26308124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633186T Expired - Lifetime DE69633186T2 (de) 1995-11-16 1996-11-05 Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren

Country Status (9)

Country Link
EP (1) EP0862622B1 (de)
JP (1) JP4173544B2 (de)
AT (1) ATE274053T1 (de)
AU (1) AU7564396A (de)
DE (1) DE69633186T2 (de)
DK (1) DK0862622T3 (de)
ES (1) ES2227614T3 (de)
PT (1) PT862622E (de)
WO (1) WO1997018303A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525703D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Screening method
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
CA2214841A1 (en) * 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
SE9801530D0 (sv) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Ab Method for screening
US6555732B1 (en) 1998-09-14 2003-04-29 Pioneer Hi-Bred International, Inc. Rac-like genes and methods of use
DE69941877D1 (de) * 1998-10-16 2010-02-11 Otsuka Pharma Co Ltd Neovaskular-spezifische peptide
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
WO2000050452A1 (en) * 1999-02-26 2000-08-31 University College London Mutants of rac protein
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
WO2000056866A2 (en) * 1999-03-19 2000-09-28 Aventis Pharmaceuticals Products Inc. Akt-3 nucleic acids, polypeptides, and uses thereof
US20040096448A1 (en) * 2000-05-30 2004-05-20 Karin Molling Nucleic acid molecules encoding a protein interacting with ser/thr kinase akt
US6689807B1 (en) 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
GB0227562D0 (en) 2002-11-26 2002-12-31 Novartis Forschungsstiftung Phorphorylated NDR Kinase
AU2005287169A1 (en) * 2004-09-17 2006-03-30 Exelixis, Inc. PIK4CA as modifier of the RAC pathway and methods of use
CA2922575C (en) * 2013-11-01 2022-10-11 Newsouth Innovations Pty Limited Pharmaceutical combinations for the treatment of cancer

Also Published As

Publication number Publication date
AU7564396A (en) 1997-06-05
ES2227614T3 (es) 2005-04-01
DE69633186T2 (de) 2005-08-18
EP0862622A1 (de) 1998-09-09
ATE274053T1 (de) 2004-09-15
JP2000500746A (ja) 2000-01-25
DK0862622T3 (da) 2004-12-20
JP4173544B2 (ja) 2008-10-29
WO1997018303A1 (en) 1997-05-22
EP0862622B1 (de) 2004-08-18
PT862622E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
ATE274053T1 (de) Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
Semenov et al. Threshold sensing through a synthetic enzymatic reaction–diffusion network
ATE315663T1 (de) Universelle zielsequenzen zur identifizierung von tierarten
Salamanna et al. An in vitro 3D bone metastasis model by using a human bone tissue culture and human sex-related cancer cells
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
AU1402788A (en) Vascular anticoagulant proteins
WO2003099781A3 (en) METHODS FOR THE IDENTIFICATION OF IKKα FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
TW200504223A (en) Methods of assessment of drug metabolizing enzymes
DE69637391D1 (de) Modifizierte myelin proteinmoleküle
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EA200100160A1 (ru) Новые способы идентификации биомолекул лигандов и мишеней
ATE364093T1 (de) Biologische indikatoren zur gültigkeitserklärung eines prionsterilisierungsprozess
Ritchie et al. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI‐2)
WO2003021225A3 (en) Method for classification of anti-psychotic drugs
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
DE69628936D1 (de) Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
WO2003044170A3 (en) Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
DE3855007D1 (de) METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN
ATE208504T1 (de) Komplex-gebundene hemmstoffe aktivierbarer stoffwechselenzyme als molekulare marker zur diagnostik und therapieüberwachung
ATE384804T1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND ZUR DETEKTION VON PROLIFERATIVEN STÖRUNGEN DIE MIT DER ÜBEREXPRESSION DES MENSCHLICHEN ßTRANSKETOLASE LIKE-1ß GENS IN ZUSAMMENHANG STEHEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN